Literature DB >> 12097264

Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion.

Cameron J Koch1, Patricia R Oprysko, A Lee Shuman, W Timothy Jenkins, Gordon Brandt, Sydney M Evans.   

Abstract

One method to make hypoxic, radioresistant cells more radiation sensitive has been to increase the oxygen carrying capacity of normal blood using liquid perfluorochemical emulsions combined with breathing high pO2 gases. We investigated the ability of dodecafluoropentane (DDFP) to sensitize the moderately radiation-resistant Morris 7777 hepatoma based on our previous inability to modify the radiation response of this tumor. DDFP is used in very small quantities compared with perfluorchemicals reported previously. Rats under isoflurane anesthesia were administered EF5 3 h before irradiation to monitor the pretreatment level of tissue hypoxia. At -40 min, DDFP was administered i.v. at 3.5 ml/kg over 30 min. At -10 min, the rats were either continued with air (for controls) or switched to carbogen. The tumors were then irradiated and processed for evaluation of radiation response. Tumor-cell survival for DDFP treatment with air-breathing animals was not significantly different from controls treated without DDFP. Carbogen alone provided minimal sensitization. DDFP plus carbogen caused dramatic radiosensitization, and the radiation response of cells from these tumors was the same as a completely aerobic radiation response. DDFP plus carbogen appears to completely reverse the hypoxic cell radioresistance in this tumor model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097264

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Conductive thermal ablation of 4T1 murine breast carcinoma reduces severe hypoxia in surviving tumour.

Authors:  Beata D Przybyla; Gal Shafirstein; Nathan A Koonce; Jessica S Webber; Robert J Griffin
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

Review 2.  Phase-change contrast agents for imaging and therapy.

Authors:  Paul S Sheeran; Paul A Dayton
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dodecafluoropentane Nano-Emulsion-Preliminary Findings.

Authors:  Jennifer L H Johnson; Rafael A Leos; Amanda F Baker; Evan C Unger
Journal:  J Biomed Nanotechnol       Date:  2015-02       Impact factor: 4.099

4.  Liposome encapsulated perfluorohexane enhances radiotherapy in mice without additional oxygen supply.

Authors:  Linfeng Xu; Xuefeng Qiu; Yanting Zhang; Kai Cao; Xiaozhi Zhao; Jinhui Wu; Yiqiao Hu; Hongqian Guo
Journal:  J Transl Med       Date:  2016-09-20       Impact factor: 5.531

Review 5.  Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.

Authors:  Kaitlin Graham; Evan Unger
Journal:  Int J Nanomedicine       Date:  2018-10-04

6.  A Robust Oxygen Microbubble Radiosensitizer for Iodine-125 Brachytherapy.

Authors:  Sheng Peng; Ruyuan Song; Qingguang Lin; Yanling Zhang; Yuanzhong Yang; Ma Luo; Zhihui Zhong; Xiaonan Xu; Ligong Lu; Shuhuai Yao; Fujun Zhang
Journal:  Adv Sci (Weinh)       Date:  2021-02-10       Impact factor: 16.806

Review 7.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

Review 8.  Improving the performance of phase-change perfluorocarbon droplets for medical ultrasonography: current progress, challenges, and prospects.

Authors:  Paul S Sheeran; Paul A Dayton
Journal:  Scientifica (Cairo)       Date:  2014-06-01

Review 9.  Radioresistance in Glioblastoma and the Development of Radiosensitizers.

Authors:  Md Yousuf Ali; Claudia R Oliva; Abu Shadat M Noman; Bryan G Allen; Prabhat C Goswami; Yousef Zakharia; Varun Monga; Douglas R Spitz; John M Buatti; Corinne E Griguer
Journal:  Cancers (Basel)       Date:  2020-09-03       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.